论文部分内容阅读
目的探讨β-_2受体激动剂在支气管哮喘治疗中的合理应用。方法选取2015年6月~2016年6月在我院住院的178例支气管哮喘患者进行观察,根据治疗方式不同分为对照组(76例)和研究组(102例),对照组患者予以布地奈德治疗,研究组患者在对照组基础上加用β_2受体激动剂,并比较两组患者临床效果和不良反应发生率。结果研究组患者临床治疗总有效率与对照组比较差异具有统计学意义(P<0.05);两组患者不良反应发生率均轻微,研究组患者不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论论β_2受体激动剂联合布地奈德能有效提高支气管哮喘患者临床效果,且不良反应轻微,该方法安全可靠。
Objective To investigate the rational use of β-2 receptor agonists in the treatment of bronchial asthma. Methods A total of 178 patients with bronchial asthma hospitalized in our hospital from June 2015 to June 2016 were selected and divided into control group (n = 76) and study group (n = 102) according to different treatment methods. Patients in the control group were given budesonide Germany treatment, the study group patients in the control group based on the use of β 2 receptor agonist, and clinical outcomes and adverse reactions in both groups were compared. Results The total effective rate of clinical treatment in study group was significantly lower than that in control group (P <0.05). The incidence of adverse reactions in both groups was slight. The incidence of adverse reactions in study group was not significantly different from that in control group (P> 0.05). Conclusions The combination of β 2 receptor agonist and budesonide can effectively improve the clinical effect of asthma patients with mild adverse reactions. The method is safe and reliable.